DSGNDesign Therapeutics, Inc.

14.99USD-5.96%Mkt Cap: 938.10M $P/E:

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The compa…

Key Statistics

Company
Market Cap938.10M $
Enterprise Value769.04M $
Revenue (TTM)
Gross Profit-58.78M $
Net Income (TTM)-69.79M $
Revenue/Share
Last Price14.99 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees55
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN
Valuation
P/E (Trailing)
P/E (Forward)-9.77
PEG
EV/EBITDA-9.82
EV/Revenue
P/S
P/B4.82
EPS (TTM)-1.15
EPS (Forward)-1.59
52W Range
4.68082% of range17.25
52W High17.25 USD
52W Low4.680 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-32.84%
ROA-30.85%
Growth
Revenue Growth
Earnings Growth
Cash Flow & Leverage
Operating CF-54.36M $
CapEx (TTM)193.00K $
FCF Margin
FCF Yield-3.45%
Net Debt-204.73M $
Net Debt/EBITDA2.61
Balance Sheet
Debt/Equity0.01
Current Ratio18.86
Quick Ratio18.61
Book Value/Sh3.226 USD
Cash/Share3.314 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Analyst Consensus
Rating
Target (Mean)21.00 USD
Upside (mean)+40.1%
Target Range20.00 USD22.00 USD
$20.00+40.1% to mean$22.00
# Analysts6
Ownership
Shares Out.62.58M
Float36.19M
Insiders31.87%
Institutions78.58%
Short Interest
Short Ratio8.4d
Short % Float12.60%
Short % Out.9.51%
Shares Short5.95M
Short (prev mo.)5.72M
Technical
SMA 5013.38 (+12.1%)
SMA 20011.19 (+33.9%)
Beta1.64
S&P 52W Chg18.16%
Avg Vol (30d)483.57K
Avg Vol (10d)503.48K
Technical Indicators
RSI (14)61.2
MACD0.6426
MACD Signal0.4238
MACD Hist.+0.2188
BB Upper16.18 USD
BB Middle13.51 USD
BB Lower10.83 USD
BB Width39.61%
ATR (14)0.7838 USD
Vol Ratio (20d)1.27x